logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

Daniele Rossini

University of Florence
H指数:30
被引数:3,655

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real world outcomes of perioperative FLOT in an Italian cohort of resectable gastric cancer: long term follow-up of prospective observational Real-FLOT study

可切除胃癌意大利队列中围手术期FLOT的长期随访真实世界结果：前瞻性观察性Real-FLOT研究

BMC Cancer
IF3.4
2026-09-170
OAAI
Irene Valle; Elisa Giommoni; Daniele Rossini; Chiara Carmen Miceli; Lorenzo Fornaro; Francesco Iachetta; Carmelo Pozzo; Maria Antonietta Satolli; Andrea Spallanzani; Marco Puzzoni; Francesca Bergamo; Michele Sisani; Vincenzo Formica; Filippo Giovanardi; Antonia Strippoli; Michele Prisciandaro; Samantha Di Donato; Giuseppe Caropreso; Francesca Salani; Alessandra Romagnani; Daniele Lavacchi; Ferdinando De Vita; Lorenzo Antonuzzo
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial

Antonuzzo, L.; Lavacchi, D.; Spada, F.; Marconcini, R.; Gelsomino, F.; Amoroso, V.; Cosso, F.; Pellegrini, E.; Scolari, F.; Sparano, C.; 等. 依维莫司作为晚期神经内分泌肿瘤的维持疗法：来自MAVERIC II期试验的结果. Oncologist 2026, 31, oyaf432. [Google Scholar] [CrossRef] [PubMed]

Oncologist
IF4.2
2026-03-010
PRE
Antonuzzo, Lorenzo; Lavacchi, Daniele; Spada, Francesca; Marconcini, Riccardo; Gelsomino, Fabio; Amoroso, Vito; Cosso, Federica; Pellegrini, Elisa; Scolari, Federico; Sparano, Clotilde; Massaro, Giulia; Giommoni, Elisa; Messerini, Luca; Rossini, Daniele; Brugia, Marco; Di Costanzo, Francesco; Boni, Luca; Milione, Massimo; Pillozzi, Serena; Fazio, Nicola
Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials

评估肝转移性结直肠癌中转移灶切除的临床获益：一项基于IPD的九项随机试验的合并分析

ESMO Open
IF8.3
2026-01-010
OA
M.M. Germani; Ada Taravella; Daniele Rossini; Lena Weiss; Federica Morano; F. Bergamo; Vittorio Studiale; Arndt Stahler; M. Carullo; L. Salvatore; K. Heinrich; Alessandro Passardi; D.P. Modest; C. Antoniotti; Massimo Di Maïo; M. Landi; Emiliano Tamburini; Sebastian Stintzing; Gianluca Masi; Sara Lonardi; F. Pietrantonio; V. Heinemann; C. Cremolini
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine–nab-paclitaxel failure: a propensity score-matched analysis

二线5-FU联合纳米脂质体伊立替康与FOLFOX/XELOX方案对比：在吉西他滨–白蛋白结合型紫杉醇治疗失败后的转移性胰腺癌中的倾向性评分匹配分析

ESMO Open
IF8.3
2025-11-070
OAAI
G. Trovato; D. Rossini; A. Guidolin; Y.-Y. Su; Y.-S. Shan; N.-J. Chiang; W.-C. Chou; L.-Y. Bai; C. Bagalà; M. Bensi; M. Niger; S. Marchesi; S.K. Garattini; A. Michelotti; A. Pretta; M. Scartozzi; C. Vivaldi; L. Bartalini; L. Procaccio; F. Bergamo; L. Antonuzzo; L.-T. Chen; L. Salvatore; G. Tortora
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study

关于肌肉浸润性膀胱癌围手术期化疗的疗效和利用率的意大利临床实践快照: realsitle研究

IN VIVO
IF1.8
2025-11-010
PRE
Gambale, Elisabetta; Giorgione, Roberta; Basso, Umberto; Galli, Luca; Fornarini, Giuseppe; Atzori, Francesco; Scagliarini, Sarah; Masini, Cristina; Baldazzi, Valentina; Scolari, Federico; Mela, Marinella Micol; Maruzzo, Marco; Vascotto, Ismaela Anna; Rossi, Virginia; Rossini, Daniele; Roviello, Giandomenico; Lavacchi, Daniele; Serni, Sergio; Minervini, Andrea; Pillozzi, Serena; Antonuzzo, Lorenzo
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: an individual patient data-based pooled analysis of randomized trials

FOLFOXIRI/bevacizumab与双药/bevacizumab作为不可切除的肝-only、右侧和/或RAS或BRAF突变转移性结直肠癌初始治疗的比较：一项基于个体患者数据的随机试验合并分析

European Journal of Cancer
IF7.1
2025-08-150
PRE
Carlotta Antoniotti; Federica Marmorino; Daniele Rossini; Hans Joachim Schmoll; Sara Lonardi; Giuseppe Tonini; Beatrice Borelli; Samanta Cupini; Alexander Stein; Roberto Moretto; Francesca Bergamo; Monica Ronzoni; Marco Maria Germani; Alberto Zaniboni; Roberta Fazio; Maria Caterina De Grandis; Elena Ongaro; Gianluca Masi; Chiara Cremolini
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset

pT4N0结肠癌的预后影响与临床管理：来自大型、多中心、国际、真实世界数据集的数据

ESMO Open
IF8.3
2025-07-150
OAAI
V. Daprà; A. Gandini; F. Schietroma; D. Rossini; A. Boccaccino; G. Caira; M.A. Calegari; F. Zoratto; M. Costantini; V. Formica; M. Rofei; G. Mauri; E. Bonazzina; S. Siena; M.L. Iaia; C. Signorelli; L. Antonuzzo; S. Tamberi; C. Foppa; A. Spinelli; G. Tortora; A. Santoro; J. Taieb; A. Puccini; L. Salvatore
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies

FOLFOXIRI和FOLFOX/FOLFIRI两种一线方案，无论是否联合贝伐珠单抗，其相对剂量强度均会影响转移性结直肠癌患者的预后：TRIBE和TRIBE2研究的合并分析

EUROPEAN JOURNAL OF CANCER
IF7.1
2025-06-010
PRE
Moretto, R.; Rossini, D.; Polito, Mariam Grazia; Antoniotti, Carlotta; Intini, Rossana; Conca, Veronica; Andena, Paola; Carullo, Martina; Salvatore, Lisa; Germani, Marco Maria; Bergamo, Francesca; Passardi, Alessandro; Ciraci, Paolo; Tamburini, Emiliano; Boccaccio, Chiara; Zaniboni, Alberto; Masi, Gianluca; Pietrantonio, Filippo; Lonardi, Sara; Cremolini, C.
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
ESMO OPEN
IF8.3
2025-02-010
OAAI
Antoniotti, C.; Carullo, M.; Rossini, D.; Pietrantonio, F.; Salvatore, L.; Lonardi, S.; Tamberi, S.; Sciortino, C.; Conca, V.; Calegari, M. A.; Ciraci, P.; Tamburini, E.; Bergamo, F.; Boccaccio, C.; Passardi, A.; Ritorto, G.; Ugolini, C.; Aprile, G.; Galon, J.; Cremolini, C.
Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO

评估不可切除的转移性结直肠癌一线治疗中疾病进展风险的评估，以指导放射学评估的间隔：AIO和GONO进行的十一项随机试验的分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Germani, M. M.; Heinemann, V.; Rossini, D.; von Weikersthal, L. Fischer; Morano, F.; Heinrich, K.; Stahler, A.; Bergamo, F.; Kaiser, F.; Decker, T.; Salvatore, L.; Weiss, L.; Russo, A.; Fuchs, M.; Prete, A. A.; Antoniotti, C.; Masi, G.; Stintzing, S.; Cremolini, C.; Modest, D. P.
Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience

老年结直肠癌患者中一线免疫检查点抑制剂的疗效与安全性：一项意大利真实世界多中心研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Boccaccino, A.; Frapoli, M.; Rossini, D.; Salvatore, L.; Passardi, A.; Papiani, G.; Valsecchi, A. A.; Puccini, A.; Massaro, G.; Santucci, S.; Guidolin, A.; Spring, A.; Romagnani, E.; Tamberi, S.
Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A translational analysis of the TRIPLETE trial
ANNALS OF ONCOLOGY
IF65.4
2024-06-010
PRE
Conca, V.; Carullo, M.; Vignali, P.; Rossini, D.; Germani, M. M.; Bergamo, F.; Pietrantonio, F.; Borelli, B.; Marmorino, F.; Giordano, M.; Randon, G.; Taravella, A.; Cerantola, R.; Buonadonna, A.; Cappetta, A.; Zaniboni, A.; Antonuzzo, L.; Masi, G.; Ugolini, C.; Cremolini, C.
The presence of liver metastases does not predict resistance to immunotherapy in proficient MMR metastatic colorectal cancer (mCRC): A secondary analysis of the AtezoTRIBE study
ANNALS OF ONCOLOGY
IF65.4
2024-06-010
PRE
Carullo, M.; Antoniotti, C.; Rossini, D.; Marmorino, F.; Raimondi, A.; Salvatore, L.; Lonardi, S.; Tamberi, S.; Vetere, G.; Prisciandaro, M.; Schietroma, F.; Ramundo, M.; Pircher, C. C.; Conca, V.; Perissinotto, E.; Passardi, A.; Aprile, G.; Ugolini, C.; Galon, J.; Cremolini, C.

研究方向

暂未获取到该数据
C
Chiara Cremolini
H 指数:65论文数:976被引数:2.0万
S
Sara Lonardi
H 指数:83论文数:1,229被引数:3.4万
F
Filippo Pietrantonio
H 指数:61论文数:1,034被引数:1.6万
C
Carlotta Antoniotti
H 指数:34论文数:309被引数:7,810
A
Alfredo Falcone
H 指数:89论文数:1,289被引数:4.1万
R
Roberto Moretto
H 指数:28论文数:188被引数:3,204
F
Federica Marmorino
H 指数:30论文数:186被引数:3,590
G
Gianluca Masi
H 指数:58论文数:574被引数:2.0万
A
Alessandra Boccaccino
H 指数:23论文数:124被引数:1,882
F
Francesca Bergamo
H 指数:47论文数:565被引数:8,917